PulseSight Therapeutics is a clinical‑stage biotech developing non‑viral gene therapies for ophthalmic diseases, primarily targeting age‑related macular degeneration (AMD). Its lead candidate, PST‑611, is designed to treat both dry AMD/Geographic Atrophy and wet AMD, and has completed Phase I dosing with positive safety and efficacy signals. The company leverages viral‑free delivery platforms to provide durable retinal treatments that aim to reduce the need for frequent injections.
Funding
$54.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PBFounders
Product
Problem
Current treatments for age‑related macular degeneration rely on repeated intravitreal injections of viral‑based gene therapies or anti‑VEGF drugs, which carry risks of immune reactions, limited durability, and high treatment burden for patients.
Solution
PulseSight Therapeutics develops non‑viral gene therapy platforms that deliver therapeutic genes directly to retinal cells without using viral vectors. Their lead candidate, PST‑611, is administered via a single intravitreal injection and is designed to provide sustained expression of a therapeutic protein to address both dry (geographic atrophy) and wet forms of AMD. Early-phase clinical data demonstrate a favorable safety profile, supporting the potential for a durable, low‑frequency treatment that could reduce the need for ongoing injections and improve patient outcomes.
Target Audience
Primary customers are ophthalmologists and retinal specialists treating patients with age‑related macular degeneration, as well as healthcare systems seeking long‑acting, low‑burden therapeutic options for AMD.
Features
- Non‑viral nanoparticle delivery system engineered for efficient retinal cell transfection
- Single intravitreal administration delivering a therapeutic gene with sustained expression
- Platform designed to avoid viral vector‑associated immunogenicity and manufacturing complexity
- Applicable to both geographic atrophy (dry AMD) and neovascular (wet AMD) indications
- Clinical-stage development with Phase I safety data presented at ARVO 2026